Abstract:Importance: Dapsone-induced hypersensitivity syndrome (DHS) is a life-threatening adverse drug reaction. Based on available epidemiologic studies, HLA genotypes may play an important role in DHS. Objective: To assess the association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions (cADRs). Data sources: Human studies investigating associations between HLA-B*1301 and dapsone-induced cADRs were systematically searched without language restriction from the inception of each database until September 12, 2017, in PubMed, the Human Genome Epidemiology Network), and the Cochrane Library. Combinations of HLA genotypes, dapsone, and synonymous terms were used; reference lists were searched in selected articles. Study selection: Two reviewers identified studies investigating the associations between HLA-B*1301 and dapsone-induced cADRs that reported sufficient data for calculating the frequency of HLA-B*1301 carriers among case and control patients, in which all patients received dapsone before HLA-B*1301 screening. An initial search of the databases identified 391 articles, of which 3 studies (2 in Chinese populations and 1 in a Thai population) met the inclusion criteria. Data extraction and synthesis: Overall odds ratios (ORs) with 95% CIs were calculated using a random-effects model to determine the association between HLA-B*1301 and dapsone-induced cADRs. Subgroup analyses by type of cADR were also performed. PRISMA guidelines were used to abstract and assess data. Main outcomes and measures: Primary outcomes were associations between HLA-B*1301 and dapsone-induced cADRs in dapsone-tolerant controls. The outcomes are reported as overall OR. Statistical heterogeneity was assessed using the Q statistic and I2 tests. Results: From the 3 included studies, there were 111 unique patients with dapsone-induced cADRs (subsequently used in the meta-analysis), 1165 dapsone-tolerant patients, and 3026 healthy controls. The cases included 64 men and 49 women (2 patients were missing from the meta-analysis; 1 each from 2 of the 3 studies); mean age was 39.7 years. An association between HLA-B*1301 and dapsone-induced cADRs was identified (summary OR, 43.0; 95% CI, 24.0-77.2). Subgroup analyses among types of cADRs produced similar findings in DHS (OR, 51.7; 95% CI, 16.9-158.5), dapsone-induced severe cADRs (Stevens-Johnson syndrome and toxic epidermal necrolysis [SJS/TEN] plus drug rash [adverse skin reaction to a drug] along with eosinophilia and systemic symptoms [DRESS]) (OR, 54.0; 95% Cl, 8.0-366.2), dapsone-induced SJS/TEN (OR, 40.5; 95% CI, 2.8-591.0), and dapsone-induced DRESS (OR, 60.8; 95% CI, 7.4-496.2). There was no heterogeneity (I2 = 0%, P = .38). Conclusions and relevance: Associations between HLA-B*1301 and dapsone-induced cADRs were found in dapsone-tolerant and healthy control groups. For patient safety, genetic screening for HLA-B*1301 in Asian populations before dapsone therapy is warranted.

Update on HLA-B*15:02 allele associated with adverse drug reactions

Association Between HLA-B∗46:01 and Cutaneous Adverse Drug Reactions in Han Chinese

HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.

The association between HLA-B variants and amoxicillin-induced severe cutaneous adverse reactions in Chinese han population

HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients.

Toxicology, Including Therapeutic Drug Monitoring

Hla-B*58:01 Allele is Associated with Augmented Risk for Both Mild and Severe Cutaneous Adverse Reactions Induced by Allopurinol in Han Chinese

HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions.

HLA-A*02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population

<i>HLA-A*02:01</i> allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population

994 Risk and Association of HLA Alleles with Methimazole Induced Cutaneous Adverse Reactions in Chinese Han Population

Associations Between Human Leukocyte Antigen Polymorphisms and Hypersensitivity to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus: a Meta-Analysis.

Correlation of Patient HLA Class I Genotypes with Severe Immune-Related Adverse Events: A Retrospective Study in Chinese Population.

HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population

Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions

Association between germ-line HLA and immune-related adverse events

Human Leukocyte Antigen B14:01 and B35:01 Are Associated With Trimethoprim‐Sulfamethoxazole Induced Liver Injury

HLA-C*12:02 is Strongly Associated with Xuesaitong-induced Cutaneous Adverse Drug Reactions

Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions